Taken together, our findings shed light on the potential of concurrently targeting both epigenetic factors and receptor tyrosine kinase signaling as a promising therapeutic approach for treating FLT3-ITD AML, particularly in R/R patients. Here, NTRK1 is linked to acute myeloid leukemia.